The disclosure relates to water-soluble pharmaceutical compositions comprising at least one therapeutically active substance and at least one compound selected from among sialoglycosphingolipids, glycosphingolipids or a mixture of sialoglycosphingolipids and glycosphingolipids, in which at least one of the therapeutically active substances is a drug with hydrophobic characteristics. In particular, the disclosure relates to injectable sterile compositions formed by nanomicelles of glycosphingolipids or modified glycosphingolipids, which can be noncovalently coated with albumin and which allow the delivery and controlled release of highly hydrophobic molecules. Hydrophobic drugs of the present disclosure include: antitumor drugs, antimycotic drugs, paclitaxel, docetaxel, doxorubicin, amphotericin B, prostaglandins, isosorbide dinitrate, testosterone, nitroglycerin, estradiol, vitamin E, cortisone, dexamethasone and its esters and betamethasone valerate. Glycosphingolipids of the present disclosure include: gangliosides, monosialogangliosides, disialogangliosides, trisialogangliosides
